Biomarkers In Retinitis Pigmentosa (BIRP)


In this study, markers of oxidative stress will be measured in the aqueous humour and plasma of RP patients compared to controls.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: June 2017

Detailed Description

People with Retinitis Pigmentosa have loss of night vision followed by loss of central vision due to damage and death of photoreceptors. One of the mechanisms causing damage is high levels of oxygen in the eye. This damage produces specific biomarkers which can be measured. In this study, these biomarkers will be assessed in people with Retinitis Pigmentosa and compared to controls.


  • Other: Anterior Chamber (AC) tap
    • Aqueous Samples will be collected for measurement of biomarkers

Arms, Groups and Cohorts

  • RP patients
    • Retinitis Pigmentosa patients
  • Controls
    • Patients who will be undergoing surgery for macular hole, epiretinal membrane, or vitreomacular traction, patients who have a retinal detachment , patients with neovascular age related macular degeneration and patients with diabetic retinopathy.

Clinical Trial Outcome Measures

Primary Measures

  • Aqueous levels of markers of oxidative stress in patients with RP and controls.
    • Time Frame: 2 years

Participating in This Clinical Trial

Inclusion Criteria

  • Signed informed consent and authorization of use and disclosure of protected health information – Age more than or equal to 18 years – For the study group, patients diagnosed with Retinitis Pigmentosa by the investigators – For the control group, patients undergoing vitreoretinal surgery for macular hole, epiretinal membrane, vitreomacular traction, retinal detachment, neovascular Age-related Macular Degeneration (AMD) and Diabetic Retinopathy will be eligible Exclusion Criteria:

  • Patients with active or suspected ocular or periocular infection

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 100 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Johns Hopkins University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Peter Campochiaro, MD, Principal Investigator, Johns Hopkins University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.